OBJECTIVE: Late-onset neutropenia (LON) is an adverse effect of rituximab (RTX) in hematological malignancies, a finding that was recently reported in rheumatoid arthritis (RA). The aim of our study was to estimate its incidence in RA. METHODS: We retrospectively reviewed complete blood (cell) count of patients with RA who received RTX between October 2007 and July 2011 to identify neutropenia (≤ 1.5 × 10(9)) up to 12 months following RTX. RESULTS: One hundred eight patients received RTX, median age 64 years (range 25-86). A total of 237 cycles were given. Five patients developed LON after a median of 151 days (71-184). Two developed pneumonia. CONCLUSION: LON occurs infrequently after RTX, but can present with infection.
OBJECTIVE: Late-onset neutropenia (LON) is an adverse effect of rituximab (RTX) in hematological malignancies, a finding that was recently reported in rheumatoid arthritis (RA). The aim of our study was to estimate its incidence in RA. METHODS: We retrospectively reviewed complete blood (cell) count of patients with RA who received RTX between October 2007 and July 2011 to identify neutropenia (≤ 1.5 × 10(9)) up to 12 months following RTX. RESULTS: One hundred eight patients received RTX, median age 64 years (range 25-86). A total of 237 cycles were given. Five patients developed LON after a median of 151 days (71-184). Two developed pneumonia. CONCLUSION: LON occurs infrequently after RTX, but can present with infection.
Authors: Reza Zonozi; Zachary S Wallace; Karen Laliberte; Noah R Huizenga; Jillian M Rosenthal; Eugene P Rhee; Frank B Cortazar; John L Niles Journal: Arthritis Rheumatol Date: 2020-12-29 Impact factor: 10.995
Authors: J H Salmon; P Cacoub; B Combe; J Sibilia; B Pallot-Prades; O Fain; A Cantagrel; M Dougados; E Andres; O Meyer; P Carli; E Pertuiset; I Pane; F Maurier; P Ravaud; X Mariette; J E Gottenberg Journal: RMD Open Date: 2015-06-30